This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.01311-05v1 51/1/119    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Butler, M. M. Articles by Bowlin, T. L. Search for Related Content PubMed PubMed Citation Articles by Butler, M. M. Articles by Bowlin, T. L.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2007, p. 119-127, Vol. 51, No. 1
0066-4804/07/$08.00+0     doi:10.1128/AAC.01311-05
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Antibacterial Activity and Mechanism of Action of a Novel Anilinouracil-Fluoroquinolone Hybrid Compound

Michelle M. Butler,^1* William A. LaMarr,^1, Kimberly A. Foster,^1, Marjorie H. Barnes,¹ Donna J. Skow,^1, Patrick T. Lyden,^1,¶ Lauren M. Kustigian,¹ Chengxin Zhi,² Neal C. Brown,² George E. Wright,² and Terry L. Bowlin¹

Microbiotix, Inc., Worcester, Massachusetts,¹ GLSynthesis, Inc., Worcester, Massachusetts²

Received 6 October 2005/ Returned for modification 11 November 2005/ Accepted 16 October 2006

The anilinouracils (AUs) such as 6-(3-ethyl-4-methylanilino)uracil (EMAU) are a novel class of gram-positive, selective, bactericidal antibacterials which inhibit pol IIIC, the gram-positive-specific replicative DNA polymerase. We have linked various fluoroquinolones (FQs) to the N-3 position of EMAU to generate a variety of AU-FQ "hybrids" offering the potential for targeting two distinct steps in DNA replication. In this study, the properties of a hybrid, "251D," were compared with those of representative AUs and FQs in a variety of in vitro assays, including pol IIIC and topoisomerase/gyrase enzyme assays, antibacterial, bactericidal, and mammalian cytotoxicity assays. Compound 251D potently inhibited pol IIIC and topoisomerase/gyrase, displayed gram-positive antibacterial potency at least 15 times that of the corresponding AU compound, and as expected, acted selectively on bacterial DNA synthesis. Compound 251D was active against a broad panel of antibiotic-resistant gram-positive pathogens as well as several gram-negative organisms and was also active against both AU- and FQ-resistant gram-positive organisms, demonstrating its capacity for attacking both of its potential targets in the bacterium. 251D also was bactericidal for gram-positive organisms and lacked toxicity in vitro. Although we obtained strains of Staphylococcus aureus resistant to the individual parent compounds, spontaneous resistance to 251D was not observed. We obtained 251D resistance in multiple-passage experiments, but resistance developed at a pace comparable to those for the parent compounds. This class of AU-FQ hybrids provides a promising new pharmacophore with an unusual dual mechanism of action and potent activity against antibiotic-sensitive and -resistant gram-positive pathogens.

Published ahead of print on 30 October 2006.

Present address: Biotrove, Inc., Woburn, MA.

Present address: Biovest International, Worcester, MA.

Present address: Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT.

^¶ Present address: Prime Performance, Inc., Leominster, MA.

This article has been cited by other articles:

• Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L., Morris, T. W., Roche, E. D., Yan, D., Lynch, A. S. (2008). In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus. Antimicrob. Agents Chemother. 52: 2313-2323 [Abstract] [Full Text]